HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines

被引:0
作者
Lauren E. McLemore
Constance T. Albarracin
Stephen K. Gruschkus
Roland L. Bassett
Yun Wu
Sagar Dhamne
Isaiah Yim
Kevin Lin
Isabelle Bedrosian
Nour Sneige
Hui Chen
机构
[1] The University of Texas MD Anderson Cancer Center,Department of Pathology
[2] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
[3] Baylor College of Medicine,Department of Pathology & Immunology
[4] The University of Texas MD Anderson Cancer Center,Department of Breast Surgical Oncology
[5] University of Colorado,Department of Pathology
来源
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词
amplification; HER2 overexpression; FISH; ASCO/CAP guidelines; Breast cancer; Oncotype DX;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:95 / 104
页数:9
相关论文
共 288 条
[1]  
Wolff AC(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013
[2]  
Hammond ME(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18-43
[3]  
Hicks DG(2018)Human Epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update J Clin Oncol 36 2105-2122
[4]  
Dowsett M(2016)HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials J Clin Oncol 34 3518-3528
[5]  
McShane LM(2019)American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory Am J Clin Pathol 152 479-485
[6]  
Allison KH(2007)Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer Clin Chem 53 1084-1091
[7]  
Allred DC(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826
[8]  
Bartlett JM(2011)High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study J Clin Oncol 29 4279-4285
[9]  
Bilous M(2014)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update Arch Pathol Lab Med 138 241-256
[10]  
Fitzgibbons P(1986)The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1644-1646